arrow
Back
S

Scott M. Wasserman

ionis pharmaceuticals inc.

62H-index
181Paper Count
2.5WCitation Count
Published Papers 74
Publication Date
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab
err2022-04-01
err2
errOAAI
errHonda, Satoshi; Puri, Rishi; Anderson, Todd; Kastelein, John J. P.; Brennan, Danielle M.; Kassahun, Helina; Somaratne, Ransi; Wasserman, Scott M.; Nissen, Steve E.; Nicholls, Stephen J.
errShare
errSave
C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV(vol 3, artn 100091, year 2020)
err2021-06-01
err1
errOAAI
errNelson, Adam J.; Puri, Rishi; Brennan, Danielle M.; Anderson, Todd J.; Cho, Leslie; Ballantyne, Christie M.; Kastelein, John Jp.; Koenig, Wolfgang; Kassahun, Helina; Somaratne, Ransi M.; Wasserman, Scott M.; Nissen, Steven E.; Nicholls, Stephen J.
errShare
errSave
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
err2020-09-01
err5
errOAAI
errNelson, Adam J.; Puri, Rishi; Brennan, Danielle M.; Anderson, Todd J.; Cho, Leslie; Ballantyne, Christie M.; Kastelein, John Jp; Koenig, Wolfgang; Kassahun, Helina; Somaratne, Ransi M.; Wasserman, Scott M.; Nissen, Steven E.; Nicholls, Stephen J.
errShare
errSave
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
errSTROKE
IF8.9
err2020-05-01
err118
errOAAI
errGiugliano, Robert P.; Pedersen, Terje R.; Saver, Jeffrey L.; Sever, Peter S.; Keech, Anthony C.; Bohula, Erin A.; Murphy, Sabina A.; Wasserman, Scott M.; Honarpour, Narimon; Wang, Huei; Lira Pineda, Armando; Sabatine, Marc S.
errShare
errSave
What Gets Measured, Gets Done: Understanding and Addressing Middle-Class Challenges
err2019-07-08
err2
PREAI
errEly, Todd L.; Propheter, Geoffrey; Jones, Rich; Wasserman, Scott
errShare
errSave
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
err2019-03-19
err561
errOAAI
errO'Donoghue, Michelle L.; Fazio, Sergio; Giugliano, Robert P.; Stroes, Erik S. G.; Kanevsky, Estella; Gouni-Berthold, Ioanna; Im, KyungAh; Pineda, Armando Lira; Wasserman, Scott M.; Ceska, Richard; Ezhov, Marat V.; Jukema, J. Wouter; Jensen, Henrik K.; Tokgozoglu, S. Lale; Mach, Francois; Huber, Kurt; Sever, Peter S.; Keech, Anthony C.; Pedersen, Terje R.; Sabatine, Marc S.
errShare
errSave
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab An Analysis of FOURIER Trial Data
err2019-01-01
err42
errOAAI
errQamar, Arman; Giugliano, Robert P.; Keech, Anthony C.; Kuder, Julia F.; Murphy, Sabina A.; Kurtz, Christopher E.; Wasserman, Scott M.; Sever, Peter S.; Pedersen, Terje R.; Sabatine, Marc S.
errShare
errSave
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
err2018-12-18
err99
errOAAI
errStiekema, Lotte C. A.; Stroes, Erik S. G.; Verweij, Simone L.; Kassahun, Helina; Chen, Lisa; Wasserman, Scott M.; Sabatine, Marc S.; Mani, Venkatesh; Fayad, Zahi A.
errShare
errSave
Leveraging electronic health records for clinical research
err2018-08-01
err40
errOAAI
errRaman, Sudha R.; Curtis, Lesley H.; Temple, Robert; Andersson, Tomas; Ezekowitz, Justin; Ford, Ian; James, Stefan; Marsolo, Keith; Mirhaji, Parsa; Rocca, Mitra; Rothman, Russell L.; Sethuraman, Barathi; Stockbridge, Norman; Terry, Sharon; Wasserman, Scott M.; Peterson, Eric D.; Hernandez, Adrian F.
errShare
errSave
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation Insights From the FOURIER Trial
err2018-08-01
err110
errOAAI
errMartin, Seth S.; Giugliano, Robert P.; Murphy, Sabina A.; Wasserman, Scott M.; Stein, Evan A.; Ceska, Richard; Lopez-Miranda, Jose; Georgiev, Borislav; Lorenzatti, Alberto J.; Tikkanen, Matti J.; Sever, Peter S.; Keech, Anthony C.; Pedersen, Terje R.; Sabatine, Marc S.
errShare
errSave
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
err2018-03-16
err120
errOAAI
errWatts, Gerald F.; Chan, Dick C.; Somaratne, Ransi; Wasserman, Scott M.; Scott, Rob; Marcovina, Santica M.; Barrett, P. Hugh R.
errShare
errSave
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk
err2017-11-28
err18
errOAAI
errGraham, Ian; Shear, Chuck; De Graeff, Pieter; Boulton, Caroline; Catapano, Alberico L.; Stough, Wendy Gattis; Carlsson, Stefan C.; De Backer, Guy; Emmerich, Joseph; Greenfeder, Scott; Kim, Albert M.; Lautsch, Dominik; Nguyen, Tu; Nissen, Steven E.; Prasad, Krishna; Ray, Kausik K.; Robinson, Jennifer G.; Sasiela, William J.; Slot, Karsten Bruins; Stroes, Erik; Thuren, Tom; Van der Schueren, Bart; Velkovski-Rouyer, Maja; Wasserman, Scott M.; Wiklund, Olov; Zouridakis, Emmanouil
errShare
errSave
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
errLANCET
IF88.5
err2017-10-01
err484
PREAI
errGiugliano, Robert P.; Pedersen, Terje R.; Park, Jeong-Gun; De Ferrari, Gaetano M.; Gaciong, Zbigniew A.; Ceska, Richard; Toth, Kalman; Gouni-Berthold, Ioanna; Lopez-Miranda, Jose; Schiele, Francois; Mach, Francois; Ott, Brian R.; Kanevsky, Estelle; Pineda, Armando Lira; Somaratne, Ransi; Wasserman, Scott M.; Keech, Anthony C.; Sever, Peter S.; Sabatine, Marc S.
errShare
errSave
Cognitive Function in a Randomized Trial of Evolocumab
err2017-08-17
err362
PREAI
errGiugliano, Robert P.; Mach, Francois; Zavitz, Kenton; Kurtz, Christopher; Im, Kyungah; Kanevsky, Estella; Schneider, Jingjing; Wang, Huei; Keech, Anthony; Pedersen, Terje R.; Sabatine, Marc S.; Sever, Peter S.; Robinson, Jennifer G.; Honarpour, Narimon; Wasserman, Scott M.; Ott, Brian R.
errShare
errSave
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference
err2017-07-22
err9
PREAI
errPovsic, Thomas J.; Scott, Rob; Mahaffey, Kenneth W.; Blaustein, Robert; Edelberg, Jay M.; Lefkowitz, Martin P.; Solomon, Scott D.; Fox, Jonathan C.; Healy, Kevin E.; Khakoo, Aarif Y.; Losordo, Douglas W.; Malik, Fady I.; Monia, Brett P.; Montgomery, Rusty L.; Riesmeyer, Jeffrey; Schwartz, Gregory G.; Zelenkofske, Steven L.; Wu, Joseph C.; Wasserman, Scott M.; Roe, Matthew T.
errShare
errSave
Response by Watts et al to Letter Regarding Article, Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
err2017-07-04
err1
errOAAI
errWatts, Gerald F.; Chan, Dick C.; Somaratne, Ransi; Wasserman, Scott M.; Sabatine, Marc S.
errShare
errSave
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies
err2017-05-09
err67
errOAAI
errToth, Peter P.; Descamps, Olivier; Genest, Jacques; Sattar, Naveed; Preiss, David; Dent, Ricardo; Djedjos, Constantine; Wu, Yuna; Geller, Michelle; Uhart, Magdalena; Somaratne, Ransi; Wasserman, Scott M.
errShare
errSave
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
err2017-05-04
err4.1K
errOAAI
errSabatine, Marc S.; Giugliano, Robert P.; Keech, Anthony C.; Honarpour, Narimon; Wiviott, Stephen D.; Murphy, Sabina A.; Kuder, Julia F.; Wang, Huei; Liu, Thomas; Wasserman, Scott M.; Sever, Peter S.; Pedersen, Terje R.
errShare
errSave